Journal
CELL REPORTS
Volume 16, Issue 1, Pages 120-132Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2016.05.085
Keywords
-
Categories
Funding
- Cancer Initiative of North Carolina and Free to Breathe
- NIH [T32HL094296]
- European Research Council [FP7-IDEAS-ERC-StG-2010-260524-KRASHIMPE]
- U.S. Department of Veterans Affairs
- Vanderbilt-Ingram Cancer Center Spore
Ask authors/readers for more resources
Although epithelial NF-kappa B signaling is important for lung carcinogenesis, NF-kappa B inhibitors are ineffective for cancer treatment. To explain this paradox, we studied mice with genetic deletion of IK kappa beta in myeloid cells and found enhanced tumorigenesis in Kras(G12D) and urethane models of lung cancer. Myeloid-specific inhibition of NF-kappa B augmented pro-IL-1 beta processing by cathepsin G in neutrophils, leading to increased IL-1 beta and enhanced epithelial cell proliferation. Combined treatment with bortezomib, a proteasome inhibitor that blocks NF-kappa B activation, and IL-1 receptor antagonist reduced tumor formation and growth in vivo. In lung cancer patients, plasma IL-1 beta levels correlated with poor prognosis, and IL-1 beta increased following bortezomib treatment. Together, our studies elucidate an important role for neutrophils and IL-1 beta in lung carcinogenesis and resistance to NF-kappa B inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available